Table 1: THEME 3 (Outcomes) Summary of Investigator-Initiated Studies/Case Series for Epoetin NHMRC NHMRC NHMRC Evidence Number of Evidence Evidence Agent Reference Indication(s) Comments on Outcomes Assessment 30 Patients Assessment 30 Assessment 30 Level of Generalisability Applicability Evidence Epoetin 33 Renal transplant 10 switches Amongst switchers epoetin dose IV A A zeta recipients at 1 month was slightly higher 10 naïve than at baseline but not statistically significant (127± 99 vs. 117± 73 UI/kg per week) No drug-related adverse effects Epoetin 34 Elderly low-risk 24 15 patients (62.5%) became IV A A alfa myelodysplastic transfusion independent and (Binocrit) syndrome patients remained free from transfusion requirement for at least 3 months Conclusion: Binocrit is promising for the treatment of anaemia of MDS patients
Table 1: THEME 3 (Outcomes) Summary of Investigator-Initiated Studies/Case Series for Epoetin Agent Reference Indication(s) Number of Patients Comments on Outcomes NHMRC Evidence Assessment 30 Level of Evidence NHMRC Evidence Assessment 30 Generalisability NHMRC Evidence Assessment 30 Applicability Epoetin zeta 33 Renal transplant recipients 10 switches 10 naïve Amongst switchers epoetin dose at 1 month was slightly higher than at baseline but not statistically significant (127± 99 vs. 117± 73 UI/kg per week) No drug-related adverse effects IV A A Epoetin alfa (Binocrit) 34 Elderly low-risk myelodysplastic syndrome patients 24 15 patients (62.5%) became transfusion independent and remained free from transfusion requirement for at least 3 months Conclusion: Binocrit is promising for the treatment of anaemia of MDS patients IV A A
biosimilars-literature-review-report.docx